Mobile

A 6-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN SRA-333 SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER S DIS...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-001477-94

A 6-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN SRA-333 SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER S DISEASE TREATED WITH A CHOLINESTERASE INHIBITOR

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to determine the safety, tolerability, and efficacy of three doses of lecozotan SR 2, 5, 10 mg in combination with a cholinesterase inhibitor in patients with mild to moderate Alzheimer s Disease over 24 weeks.

Critère d'inclusion

  • Alzheimer s Desease

Liens